Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

American Century Companies Inc. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 46.8% during the fourth quarter, according to its most recent filing with the Securities ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Biogen's treatment for neurodegenerative disorder spinal muscular atrophy (SMA) Spinraza has come under pressure in an increasingly competitive market, but the company hopes a new high-dose ...